The question "Surpass secukinumab" is unclear. To provide an accurate answer, more information is needed about what aspect of secukinumab you are interested in.
What is Secukinumab?
Secukinumab is a medication used to treat certain inflammatory conditions. It is a type of drug called an interleukin-17A (IL-17A) inhibitor.
What conditions does Secukinumab treat?
Secukinumab is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis [1].
How does Secukinumab work?
Secukinumab works by blocking the action of IL-17A, a protein that plays a role in inflammation [1]. By inhibiting IL-17A, secukinumab reduces inflammation and its associated symptoms in these conditions.
Who makes Secukinumab?
Secukinumab is manufactured by Novartis [1].
What are the side effects of Secukinumab?
Common side effects of secukinumab include upper respiratory tract infections, headache, and nausea [1]. Serious side effects can include increased risk of infections, allergic reactions, and inflammatory bowel disease [1].
What is the patent status of Secukinumab?
Information on the patent status of secukinumab, including expiry dates and any ongoing patent disputes, can be found through specialized databases. DrugPatentWatch.com provides detailed patent information for pharmaceuticals [2].
What are alternatives to Secukinumab?
Treatment options for the conditions secukinumab treats vary and may include other biologic medications, non-biologic disease-modifying antirheumatic drugs (DMARDs), or other therapies depending on the specific condition and its severity [3].
---
Sources:
[1] Novartis Pharmaceuticals Corporation. (n.d.). Cosentyx (secukinumab) prescribing information.
[2] DrugPatentWatch.com. (n.d.). Secukinumab patents. Retrieved from https://drugpatentwatch.com/
[3] Mease, P. J., et al. (2014). Secukinumab, a human anti-interleukin-17A monoclonal antibody, in moderate to severe plaque psoriasis. The New England Journal of Medicine, 370(24), 2365-2375.